Pioneering Hope, Transforming Lives

AI-driven therapies for a healthier future.

About Us

brainQr Therapeutics is developing next-generation therapies for major human diseases by targeting disordered proteins, a vast and previously largely undruggable class of biomolecules. Our mission is to harness cutting-edge scientific innovation to pioneer novel treatment strategies that address urgent unmet medical needs.

Our Technology

brainQr's AI-IDP platform enables breakthrough therapies for dynamic disordered proteins, unlocking new possibilities in neurodegeneration and oncology.

<

Our Tau-Stabilizing Lead Program

brainQr's lead program focuses on a first-in-class small molecule designed to stabilize the native structure of Tau protein. This groundbreaking approach aims to prevent tau aggregation at its earliest stage, effectively stopping Alzheimer’s disease progression before irreversible neuronal damage occurs.

Indication Target Product Candidate Discovery Preclinical Phase 1 Phase 2 Phase 3
Alzheimer’s Disease Tau BQ-141 ✔ ✔
Progressive Supranuclear Palsy Tau Tau Stabilizers ✔
ALS TDP-43 AI-IDP Stabilizers ✔

Leadership Team

Prof. Markus Zweckstetter

Prof. Markus Zweckstetter - CEO

Prof. Zweckstetter is a world-renowned expert in neurodegenerative disease research and the founder and CEO of brainQr Therapeutics. With a unique academic background in physics and business economics, Prof. Zweckstetter combines scientific rigor with a strategic business perspective.

Dr. Lisa Marie Ramirez

Dr. Lisa Marie Ramirez - Project Manager

Dr. Ramirez is a distinguished neurochemist. She obtained her Ph.D. in Chemistry from the State University of New York at Albany, USA, and subsequently performed postdoctoral studies on Tau misfolding at the German Center for Neurodegenerative Diseases (DZNE).

Scientific & Business Advisors

Prod. Dr. Anja Schneider

Prof. Dr. Anja Schneider

Prof. Dr. Anja Schneider is a renowned expert in clinical dementia research and neurodegenerative diseases. She serves as Professor of Clinical Dementia Research at the University of Bonn and heads the Clinic for Neurodegenerative Diseases and Gerontopsychiatry at Bonn University Hospital, as well as the Translational Dementia Research Group at the German Center for Neurodegenerative Diseases (DZNE). Her work has significantly advanced the understanding and clinical translation of Alzheimer’s and Tauopathies.

Dr. Arnd Steuernagel

Dr. Arnd Steuernagel

Dr. Arnd Steuernagel has extensive experience in managing and partnering drug development projects. His previous roles include Senior Vice President at the global drug development company Evotec International AG, CSO at ScilProteins, and Senior Director at DeveloGen AG.

Prof. Gerd Schnorrenberg

Prof. Gerd Schnorrenberg

Prof. Gerd Schnorrenberg has a distinguished career in medicinal chemistry and drug development. His experience includes the role as Head of Research Germany at Boehringer Ingelheim Pharma GmbH & Co. KG, where he significantly contributed to the development of several launched products, including Micardis and Pradaxa.

Supported by

SPRIND Logo nBank Logo

Projects Supported by nBank

nBank Logo

Project: brainQr AD1 (Application Nr. 87044822)
Project summary: Entwicklung wirksamer Kleinmolekülsubstanzen zur Behandlung der Alzheimer-Krankheit – This project aims to develop novel orally available small molecules for Alzheimer’s disease with improved pharmacokinetic and safety properties. It includes synthesis of new compounds, ADME-tox testing, and an in vivo pharmacokinetic study. A key goal is to generate patentable chemical matter that strengthens brainQr’s pipeline and competitiveness in tau-targeting therapies.


Project: Wirkstoffentwicklung zur Behandlung der Parkinson-Erkrankung (Application Nr. 87045909)
Project summary: Entwicklung wirksamer Kleinmolekülsubstanzen zur Behandlung der Parkinson-Erkrankung – This project aims to develop novel small-molecule therapeutics that prevent alpha-synuclein aggregation in Parkinson’s disease. New molecules will be synthesized, optimized for pharmacokinetics and safety, and evaluated through ADME-tox assays and an oral pharmacokinetic study. The goal is to identify patentable candidates with improved brain penetration and a preventive mechanism of action.